\n Az amerikai \u00c9lelmiszer- \u00e9s Gy\u00f3gyszer\u00fcgyi Hat\u00f3s\u00e1g (FDA) szerd\u00e1n enged\u00e9lyezte az Eli Lilly tests\u00falycs\u00f6kkent\u0151 tablett\u00e1j\u00e1t, ezzel a Novo Nordisk \u00fajabb versenyt\u00e1rsat kaphat a GLP\u20131 t\u00edpus\u00fa gy\u00f3gyszerek piac\u00e1n. A Lilly az \u00faj gy\u00f3gyszert orforglipron n\u00e9ven fogja forgalmazni, a k\u00e9sz\u00edtm\u00e9ny a GLP\u20131 hormont c\u00e9lozza, \u00e9s naponta egyszer kell beszedni sz\u00e1jon \u00e1t. A klinikai vizsg\u00e1latokban a betegek tests\u00falyuk 12\u201315 sz\u00e1zal\u00e9k\u00e1t vesz\u00edtett\u00e9k el.\n <\/p>\n
\n A Lilly k\u00f6z\u00f6lte, hogy \u00e1prilis 6-\u00e1n kezdi meg a Foundayo \u00e9rt\u00e9kes\u00edt\u00e9s\u00e9t a LillyDirect programj\u00e1n kereszt\u00fcl, havi 149 doll\u00e1ros \u00e1ron a legalacsonyabb d\u00f3zis eset\u00e9n az \u00f6nk\u00f6lts\u00e9gen fizet\u0151 betegek sz\u00e1m\u00e1ra, ami megegyezik a Novo tablett\u00e1j\u00e1nak \u00e1r\u00e1val. Nem sokkal k\u00e9s\u0151bb a gy\u00f3gyszer kiskereskedelmi gy\u00f3gyszert\u00e1rakban \u00e9s telemedicin\u00e1s szolg\u00e1ltat\u00f3kn\u00e1l is el\u00e9rhet\u0151 lesz \u2013 k\u00f6z\u00f6lte az indianapolisi sz\u00e9khely\u0171 v\u00e1llalat.\n <\/p>\n
\n David Ricks, a Lilly vez\u00e9rigazgat\u00f3ja \u00fajs\u00e1g\u00edr\u00f3knak arr\u00f3l besz\u00e9lt, hogy a tabletta alkalmas lesz azoknak a betegeknek, akik fogyni szeretn\u00e9nek, illetve a fogy\u00e1s megtart\u00e1s\u00e1ra t\u00f6rekszenek, \u00e9s a v\u00e1llalat t\u00f6bb mint 40 orsz\u00e1gban ny\u00fajtotta be enged\u00e9lyez\u00e9sre a k\u00e9sz\u00edtm\u00e9nyt. \u201eArra sz\u00e1m\u00edtunk, hogy m\u00e9g az id\u00e9n t\u00f6bb jelent\u0151s piacon is enged\u00e9lyt kap. Az \u00d6b\u00f6l-menti \u00e1llamok p\u00e9ld\u00e1ul \u00e1ltal\u00e1ban gyorsabban haladnak, \u00edgy az egy ilyen r\u00e9gi\u00f3 lehet\u201d \u2013 mondta Ricks. A Lilly tablett\u00e1ja b\u00e1rmelyik napszakban bevehet\u0151, \u00e9tkez\u00e9st\u0151l f\u00fcggetlen\u00fcl, szemben a Wegovy tablett\u00e1val, amit reggel \u00e9hgyomorra, minden \u00e9tel, v\u00edz vagy egy\u00e9b gy\u00f3gyszer bev\u00e9tele el\u0151tt 30 perccel kell bevenni. (Reuters<\/a>)\n <\/p>\n","protected":false},"excerpt":{"rendered":"Az amerikai \u00c9lelmiszer- \u00e9s Gy\u00f3gyszer\u00fcgyi Hat\u00f3s\u00e1g (FDA) szerd\u00e1n enged\u00e9lyezte az Eli Lilly tests\u00falycs\u00f6kkent\u0151 tablett\u00e1j\u00e1t, ezzel a Novo Nordisk…\n","protected":false},"author":2,"featured_media":49365,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[20479,2812,20476,20471,20474,20472,20469,20478,42,20473,43,34,20475,20470,5661,20477,94,14216,93,92],"class_list":{"0":"post-49364","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-vilag","8":"tag-david-ricks","9":"tag-egeszsegugy","10":"tag-elelmiszer-es-gyogyszerugyi-hatosag","11":"tag-eli-lilly","12":"tag-fda","13":"tag-foundayo","14":"tag-glp1-tipusu-gyogyszerek","15":"tag-gyogyszeripar","16":"tag-hungarian","17":"tag-lillydirect-program","18":"tag-magyar","19":"tag-news","20":"tag-novo-nordisk","21":"tag-obol-menti-allamok","22":"tag-orforglipron","23":"tag-testsulycsokkento-tabletta","24":"tag-vilag","25":"tag-wegovy","26":"tag-world","27":"tag-world-news"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@hu\/116334023464258737","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/hu\/wp-json\/wp\/v2\/posts\/49364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/hu\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/hu\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/hu\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/hu\/wp-json\/wp\/v2\/comments?post=49364"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/hu\/wp-json\/wp\/v2\/posts\/49364\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/hu\/wp-json\/wp\/v2\/media\/49365"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/hu\/wp-json\/wp\/v2\/media?parent=49364"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/hu\/wp-json\/wp\/v2\/categories?post=49364"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/hu\/wp-json\/wp\/v2\/tags?post=49364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}